A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
- 1 February 2011
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (3), 569-580
- https://doi.org/10.1158/1078-0432.ccr-10-1725
Abstract
Purpose: P-glycoprotein (Pgp) antagonists have been difficult to develop because of complex pharmacokinetic interactions and a failure to show meaningful results. Here we report the results of a pharmacokinetic and pharmacodynamic trial using a third-generation, potent, noncompetitive inhibitor of Pgp, tariquidar (XR9576), in combination with docetaxel. Experimental Design: In the first treatment cycle, the pharmacokinetics of docetaxel (40 mg/m2) were evaluated after day 1 and day 8 doses, which were administered with or without tariquidar (150 mg). 99mTc-sestamibi scanning and CD56+ mononuclear cell rhodamine efflux assays were conducted to assess Pgp inhibition. In subsequent cycles, 75 mg/m2 docetaxel was administered with 150 mg tariquidar every 3 weeks. Results: Forty-eight patients were enrolled onto the trial. Nonhematologic grade 3/4 toxicities in 235 cycles were minimal. Tariquidar inhibited Pgp-mediated rhodamine efflux from CD56+ cells and reduced 99mTc-sestamibi clearance from the liver. There was striking variability in basal sestamibi uptake; a 12% to 24% increase in visible lesions was noted in 8 of 10 patients with lung cancer. No significant difference in docetaxel disposition was observed in pairwise comparison with and without tariquidar. Four partial responses (PR) were seen (4/48); 3 in the non–small cell lung cancer (NSCLC) cohort, measuring 40%, 57%, and 67% by RECIST, and 1 PR in a patient with ovarian cancer. Conclusions: Tariquidar is well tolerated, with less observed systemic pharmacokinetic interaction than previous Pgp antagonists. Variable effects of tariquidar on retention of sestamibi in imageable lung cancers suggest that follow-up studies assessing tumor drug uptake in this patient population would be worthwhile. Clin Cancer Res; 17(3); 569–80. ©2010 AACR.Keywords
Other Versions
This publication has 51 references indexed in Scilit:
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerCritical Reviews in Oncology/Hematology, 2010
- Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance ModulatorsThe AAPS Journal, 2009
- A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with VinorelbineClinical Cancer Research, 2009
- P-glycoprotein Versus MRP1 on Transport Kinetics of Cationic Lipophilic Substrates: A Comparative Study Using [99mTc]Sestamibi and [99mTc]TetrofosminCancer Biotherapy & Radiopharmaceuticals, 2009
- Cost-Effectiveness of 99mTc-Sestamibi in Predicting Response to Chemotherapy in Patients with Lung Cancer: Systematic Review and Meta-AnalysisJournal of Nuclear Medicine, 2009
- Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®Biochemical Pharmacology, 2008
- A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell CarcinomaClinical Cancer Research, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer —Preliminaly report—Annals of Nuclear Medicine, 2000
- Comparative Study of Tc-99m MIBI and Tl-201 SPECT in Predicting Chemotherapeutic Response in Non–Small-Cell Lung CancerClinical Nuclear Medicine, 2000